Monday, October 5, 2026

IDEO Revenue Collapses 67% as AI Design Tools Gut Creative Consultancy Market

IDEO, once a $300M design consultancy, now generates under $100M in annual revenue — a decline exceeding 67%. Product and graphic design job postings have fallen sharply across multiple firms as generative AI tools automate image creation, UI design, and UX workflows. Mid-tier agencies serving fintech and financial services clients face the same structural pressure, with consolidation and closures ahead.

LM Salvado

May 18, 2026

IDEO Revenue Collapses 67% as AI Design Tools Gut Creative Consultancy Market
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...
1 The timing maps directly onto the mass adoption of generative AI tools capable of automating image creation, UI design, and UX prototyping.

Product and graphic design job postings have dropped sharply across multiple firms.1 Companies that once outsourced creative work to agencies are deploying AI tools internally instead. The economics have inverted: a task requiring a team of agency designers can now be handled by one in-house operator with an AI subscription.

The shift is structural, not cyclical. Generative image platforms, UI automation tools, and AI-assisted prototyping have compressed timelines and costs that once justified agency retainers. The price premium that design consultancies commanded — built on specialist labor and long project cycles — no longer holds against software-driven alternatives.

IDEO's numbers signal broader sector risk. Mid-tier consultancies serving fintech and financial services clients face identical pressure.1 As AI tooling embeds into in-house product workflows, external agency spend contracts. Continued revenue declines across human-centered design firms are expected, with M&A consolidation or outright closures among mid-tier agencies likely to follow.

Fintech is particularly exposed. UX and product design have historically been outsourced to specialists in that sector. AI tools now produce comparable output faster and at a fraction of the cost. Agencies that built recurring revenue on those contracts are facing structural displacement, not a temporary budget squeeze.

Design is not the first creative sector to absorb this disruption. Stock photography, copywriting, and basic illustration have already seen AI-driven price compression. Design consultancies — with higher price points and longer engagement cycles — absorbed the shock more slowly. The IDEO numbers suggest that buffer has run out.

The roles that survive will cluster at two ends: high-level creative strategy and brand direction on one side, and AI toolchain operators on the other. The mid-tier agency layer between them is contracting fast.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com